minocycline and Pyomyositis

minocycline has been researched along with Pyomyositis* in 1 studies

Other Studies

1 other study(ies) available for minocycline and Pyomyositis

Article	Year
Salvage therapy with tigecycline for recurrent infection caused by ertapenem-resistant extended-spectrum β-lactamase-producing Klebsiella pneumoniae. Diagnostic microbiology and infectious disease, 2010, Volume: 68, Issue:3 Optimal antimicrobial therapy for infections due to ertapenem-resistant Enterobacteriaceae remains undetermined. In this study, a diabetic patient with recurrent pyomyositis and osteomyelitis caused by extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae developed ertapenem resistance after imipenem/cilastatin treatment, which was a currently recommended therapy. He was finally treated successfully using tigecycline. Ertapenem resistance was in part explained by the production of SHV-type ESBL and the absence of an outer membrane protein, OmpK36. Our observation suggests that tigecycline may be an alternative for invasive infections caused by ESBL-producing Enterobacteriaceae with decreased susceptibility to carbapenem. Topics: Anti-Bacterial Agents; beta-Lactams; Diabetes Complications; Ertapenem; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Minocycline; Osteomyelitis; Pyomyositis; Recurrence; Salvage Therapy; Tigecycline; Treatment Outcome	2010

Article

Year

Salvage therapy with tigecycline for recurrent infection caused by ertapenem-resistant extended-spectrum β-lactamase-producing Klebsiella pneumoniae.

Diagnostic microbiology and infectious disease, 2010, Volume: 68, Issue:3

Optimal antimicrobial therapy for infections due to ertapenem-resistant Enterobacteriaceae remains undetermined. In this study, a diabetic patient with recurrent pyomyositis and osteomyelitis caused by extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae developed ertapenem resistance after imipenem/cilastatin treatment, which was a currently recommended therapy. He was finally treated successfully using tigecycline. Ertapenem resistance was in part explained by the production of SHV-type ESBL and the absence of an outer membrane protein, OmpK36. Our observation suggests that tigecycline may be an alternative for invasive infections caused by ESBL-producing Enterobacteriaceae with decreased susceptibility to carbapenem.

Topics: Anti-Bacterial Agents; beta-Lactams; Diabetes Complications; Ertapenem; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Minocycline; Osteomyelitis; Pyomyositis; Recurrence; Salvage Therapy; Tigecycline; Treatment Outcome

2010